WO2022028941A1 - A process for preparation of oxazole compounds - Google Patents

A process for preparation of oxazole compounds Download PDF

Info

Publication number
WO2022028941A1
WO2022028941A1 PCT/EP2021/070913 EP2021070913W WO2022028941A1 WO 2022028941 A1 WO2022028941 A1 WO 2022028941A1 EP 2021070913 W EP2021070913 W EP 2021070913W WO 2022028941 A1 WO2022028941 A1 WO 2022028941A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
compound
formula
mol
mmol
Prior art date
Application number
PCT/EP2021/070913
Other languages
French (fr)
Inventor
Werner Bonrath
Le DAI
Xixiang DAI
Qiangqiang LIU
Kun Peng
René Tobias STEMMLER
Liuhai WU
Lei Zhang
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to EP21755385.8A priority Critical patent/EP4192820A1/en
Priority to CN202180057147.2A priority patent/CN116075498A/en
Publication of WO2022028941A1 publication Critical patent/WO2022028941A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/30Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton

Definitions

  • the present invention is related to a new process for producing oxazole compounds.
  • Oxazole compounds represent a vast class of heterocyclic aromatic organic compounds. Oxazole compounds have become increasingly important because of biological activities and their use as intermediates for the preparation of new biological materials.
  • the wide range of biological activities of oxazole compounds includes anti-inflammatory, analgesic, antibacterial, antifungal, hypoglycemic, antiproliferative, anti-tuberculosis, muscle relaxant and HIV inhibitor activity.
  • 4-methyl-5-cyanooxazole is an important intermediate for producing vitamin B 6 .
  • it is mainly produced by the process comprising the steps: a) ethyl acetoacetate is chlorinated to chloroethyl acetoacetate, b) chloroethyl acetoacetate is reacted with formamide to give 4-methyl-5-oxazolecarboxylic acid ethyl ester, and c) the obtained ester is dehydrated to 4-methyl-5-cyanooxazole via 4-methyl-5- oxazole carboxamide.
  • Kun Peng Kun Peng, Qiong-Mei Zhang, Horst Pauling, Bernd-Jurgen Weimann, Ullmann's Encyclopedia of Industrial Chemistry (7th Edition) (2020)
  • the chlorination step uses chlorine and the dehydration reaction uses phosphorus pentoxide or acetic anhydride, which are toxic or corrosive.
  • the process produces many salts which cause environment problem.
  • the present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic and corrosive reagents, and reduce salts by-products with high efficiency, wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents.
  • the present invention also provides a new intermediate compound of formula (II), which can be used directly to produce the compound of formula (I) in an efficient way, wherein R is as defined above, and X is halogen.
  • the term "lower alkyl” as used refers to Ci-Cw alkyl, i.e., branched or unbranched, cyclic or non-cyclic, saturated hydrocarbon comprising 1-10 carbon atoms.
  • the "lower alkyl” is Ci-C 6 alkyl, including but not limited to methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tertbutyl, cyclobutyl, pentyl, iso-pentyl, tert-pentyl, cyclopentyl, hexyl, isohexyl, tert-hexyl, cyclohexyl, octyl, isooctyl, tert-octyl, cyclooctyl, nonyl, isononyl, tert-nonyl, cyclonony
  • aryl refers to aromatic hydrocarbon such as phenyl, benzyl, xylyl and naphthalenyl.
  • lower alkoxyl refers to the structure represented by (lower alkyl)-O-, wherein the lower alkyl is as defined above.
  • halo or halogen as used refers to a group of elements including fluorine (F), chlorine (Cl), bromine (Br) and iodine (I), preferably refers to Cl or Br.
  • salt or “salts” as used refers to any anionic and cationic complex, such as the complex formed by a cation and an anionic form of the compound of the present invention.
  • Non-limiting examples of the cation include inorganic and organic cations, e.g., cations of the alkali and alkaline earth metals, such as sodium (Na), lithium (Li), potassium (K), calcium (Ca), magnesium (Mg), and the like, as well as ammonium, quaternary ammonium, and amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, triethylammonium and ethylammonium, and the like.
  • the alkali and alkaline earth metals such as sodium (Na), lithium (Li), potassium (K), calcium (Ca), magnesium (Mg), and the like
  • ammonium, quaternary ammonium, and amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylammonium,
  • substituteduent or “substituents” as used refers to lower alkyl, lower alkoxyl, hydroxyl, halo, -NH 2 , -NO 2 , cyano and/or isocyano.
  • a compound represented by a formula or a name also cover stereoisomers thereof, including diastereomers and enantiomers, such as cis/trans-isomers or E/Z-isomers.
  • the present invention provides a process for producing a compound of formula (I), comprising the steps: a) Halogenating a compound of formula (III) or a salt thereof to produce a compound of formula (II); and b) Cyclizing the compound of formula (II) to obtain the compound of formula (I), wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents; and X is halogen.
  • R is H, or lower alkyl optionally substituted by one or more substituents. More preferably, R is H or Ci-C 6 alkyl optionally substituted by one or more substituents. Most preferably, R is H or methyl or ethyl.
  • Ri is H or methyl.
  • the salt of the compound of formula (III) may be a compound of formula (III') or its tautomeric form of formula (III"): wherein R is as defined above, and Y is a metal element such as alkali metal elements such as lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and cesium (Cs); or alkaline-earth metal elements such as beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr) and barium (Ba); and iron (ll/lll), nickel (Ni) and cobalt (Co).
  • Y is Na or K.
  • the compound of formula (III) or a salt thereof may be halogenated by a halogen or a halogen-containing compound.
  • the halogen-containing compound may be a halide salt such as alkali metal salts, alkaline-earth metal salts or quaternary ammonium salts of a halogen.
  • the halide salt include but are not limited to KF, NaF, NaBr, KBr, MgBr 2 , NaCI, KCI, RbCI, CuCI 2 , LiCI, AgCI, CaCI 2 , KI, Agl 2 , tetrabutylammonium chloride (TBAC), tetrabutylammonium bromide (TBAB), tetrabutylammonium iodide (TBAI), benzalkonium chloride (BAC), dimethyldioctadecyl-ammonium bromide (DDAB) and dodecyl trimethyl ammonium chloride (DTAC).
  • the halide is NaBr and KBr.
  • the halogen-containing compound may also be a halogen-containing organic compound.
  • suitable halogen-containing organic compound includes but is not limited to N-Bromosuccinimide (NBS), N-Chlorosuccinimide (NCS), N-lodosuccinimide (NIS), halo hydantoin such as dibromohydantoin, dichlorohydantoin and diiodohydantoin, and halo cyanuric acid such as cyanuric fluoride, trichloroisocyanuric acid, tribromoisocyanuric acid and triiodoisocyanuric acid.
  • the compound of formula (III) or a salt thereof is halogenated by a halogen, preferably in the presence of a base.
  • the base may be any organic or inorganic base or mixture thereof which can neutralize hydrogen halide generated in the reaction.
  • Example of the base includes but is not limited to as KOH, NaOH, Na 2 CO 3 , K 2 CO 3 , NaNH 2 , KF/AI 2 O 3 , potassium tert-butoxide (t- BuOK), sodium t-pentyloxide and the others.
  • the base is K 2 CO 3 .
  • the halogen may be added into the reaction in an amount of from 0.1 mol to 2 mol, preferably from 0.2 mol to 1.5 mol, more preferably from 0.3 mol to 1 mol, such as 0.3, 0.35, 0.4, 0.45. 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 and 1 mol, per 1 mol of the compound of formula (III).
  • the base may be added into the reaction in an amount of from 0.1 mol to 10 mol, preferably from 0.5 mol to 8 mol, more preferably from 1.0 mol to 5 mol, such as 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 and 5 mol, per 1 mol of the compound of formula (III).
  • the compound of formula (III) or a salt thereof is halogenated by a halide salt as defined above in the presence of an oxidant.
  • the oxidant may be any oxidant known in the art.
  • a good example of the oxidant includes but is not limited to peroxides such as hydrogen peroxide, peroxyformic acid, peroxyacetic acid, peroxypropionic acid, peroxide benzenesulfonyl acid, peroxide p-toluenesulfonyl acid and peroxide methylsulfonyl acid.
  • the halide salt may be added into the reaction in an amount of from 0.5 mol to 5.0 mol, preferably from 0.8 mol to 3.0 mol, more preferably from 1.0 mol to 2.0 mol, such as 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 2.0 mol, per 1 mol of the compound of formula (III).
  • the oxidant may be added into the reaction in an amount of from 1 mol to 10 mol, preferably from 2 mol to 8 mol, more preferably from 0.5 mol to 5 mol, preferably from 1.0 mol to 4.0 mol, more preferably from 1.5 mol to 3.0 mol, such as 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3.0 mol, per 1 mol of the compound of formula (III).
  • the halogenation is preferably carried out in the presence of an acid.
  • the acid may be any organic acid such as aliphatic acid or aromatic acid, or inorganic acid.
  • examples of the organic acid include but are not limited to lactic acid, acetic acid, formic acid, propanoic acid, butanoic acid, benzoic acid, p-methyl benzoic acid, citric acid, oxalic acid, malic acid and tartaric acid.
  • the inorganic acid examples include but are not limited to hydrochloric acid (HCI), nitric acid (HNO 3 ), phosphoric acid (H 3 PO 4 ), sulfuric acid (H 2 SO 4 ), sulfurous acid (H 2 SO 3 ), carbonic acid (H 2 CO 3 ), hydrofluoric acid (HF) and hydrobromic acid (HBr).
  • HCI hydrochloric acid
  • NO 3 nitric acid
  • SO 4 sulfuric acid
  • H 2 SO 3 sulfurous acid
  • carbonic acid H 2 CO 3
  • hydrofluoric acid HF
  • hydrobromic acid HBr
  • the acid is organic acid. More preferably, the acid is formic acid, acetic acid, benzoic acid or 4- methylbenzoic acid.
  • the acid may be added into the reaction in an amount of from 0.1 mol to 10 mol, preferably from 0.5 mol to 8.0 mol, more preferably from 1 mol to 5 mol, such as 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 5.0 mol, per 1 mol of the compound of formula (III).
  • a pH modifier such as sodium dihydrogen phosphate (NaH 2 PO 4 ) and disodium hydrogen phosphate (Na 2 HPO 4 ) may be added to maintain the pH value of the reaction mixture at from 3.5 to 6.0, preferably from 4.0 to 5.5.
  • the compound of formula (III) or a salt thereof is halogenated by a halogen-containing organic compound such as N-Bromosuccinimide (NBS), N-Chlorosuccinimide (NCS), N- lodosuccinimide (NIS), dibromohydantoin, dichlorohydantoin, diiodohydantoin, cyanuric fluoride, trichloroisocyanuric acid, tribromoisocyanuric acid and triiodoisocyanuric acid.
  • NBS N-Bromosuccinimide
  • NCS N-Chlorosuccinimide
  • N- lodosuccinimide N- lodosuccinimide
  • dibromohydantoin dichlorohydantoin
  • diiodohydantoin diiodohydantoin
  • cyanuric fluoride trichloroisocyanuric acid
  • the halogen-containing organic compound may be added into the reaction in an amount of from 0.1 mol to 5 mol, preferablyfrom 0.2 mol to 3 mol, more preferably from 0.3 mol to 2 mol, such as 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 2 mol, per 1 mol of the compound of formula (III).
  • one or more solvents may be used.
  • suitable solvents include but are not limited to esters such as ethyl acetate, propyl acetate and butyl acetate, alcohols such as methanol and ethanol, nitriles such as acetonitrile (ACN) and benzonitrile, and benzene, toluene, chlorobenzene, xylene, dimethylformamide (DMF), dichloromethane (DCM), water and others that are common-used as a solvent in the field.
  • ACN acetonitrile
  • DCM dichloromethane
  • water or butyl acetate or DCM is used as the solvent. More preferably two or more solvents which are immiscible are used. The most preferably, water and butyl acetate or DCM are used as the solvents.
  • the solvents may be added into the reaction in an amount of from 0.1 L to 20 L, preferably from 0.2 Lto 15 L, more preferably from 0.5 L to 10 L, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 and 10 L, per 1 mol of the compound of formula (III).
  • a catalyst may be used.
  • the catalyst may be any metal catalyst.
  • suitable catalyst include but are not limited to Cu(OAc) 2 , CuCI 2 , FeCI 3 , CoCI 2 , NH4VO3, Na 2 WO 4 , and heteropoly acid such as phosphotungstic acid, silicoptungstigacid (H 4 PWI 2 O 40 (hydrate) and phosphomolybdic acid, and hydrate thereof.
  • the catalyst is Cu(OAc) 2 , Na 2 WO 4 »2H 2 O, FeCI 3 »6H 2 O, CoCI 2 , CuCI 2 »2H 2 O and phosphotungstic acid hydrate.
  • the catalyst may be added into the reaction in an amount of from 0.0001 mol to 0.5 mol, preferably from 0.0005 mol to 0.4 mol, more preferably from 0.001 mol to 0.3 mol, such as 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25 and 0.3 mol, per 1 mol of the compound of formula (III).
  • the halogenation of the step a) may be carried out at room temperature.
  • the obtained compound of formula (III) may be directly used for the next step or easily isolated by any known process, such as evaporation, extraction and/or crystallization, for use in the next step.
  • the cyclization may be achieved by treating the compound of formula (II) with one or more bases.
  • the suitable bases may be strong bases, including but not limited to organic base such as l,5-diazabicyclo(4.3.0)non-5-ene (DBN), l,8-diazabicyclo[5.4.0]undec- 7-ene (DBU), 1,1,3,3-tetramethylguanidine (TMG), and alkoxide such as potassium tert-butoxide (tBuOK) and sodium t-pentyloxide; and inorganic base such as NaH, KOH, NaOH, Na 2 CO 3 , K 2 CO 3 , KF/AI 2 O 3 , Cs 2 CO 3 and NaNH 2 , and mixture thereof.
  • organic base such as l,5-diazabicyclo(4.3.0)non-5-ene (DBN), l,8-diazabicyclo[5.4.0]undec- 7-ene (DBU),
  • the base is NaH, DBN, DBU, TMG, Cs 2 CO 3 , NaNH 2 , or K 2 CO 3 , or mixture thereof.
  • the amount of the bases used in the step may be from 0.1 mol to 10 mol, preferably from 0.5 mol to 8 mol, more preferably from 1 mole to 5 moles such as 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 and 10 moles, per 1 mole of the compound of formula (II).
  • one or more solvents are preferably used.
  • the solvents suitable for the step b) of the process include but are not limited to alcohol such as n- butanol and 2,2,2-trifluorethanol (TFE); ether such as methyl tert-butyl ether (MTBE), 2-methyl tetrahydrofuran (Me-THF) and 1,4-dioxane; ester such as ethyl acetate, butylacetate, dimethyl carbonate (DMC) and propylene carbonate (PC); ketone such as cyclohexanone, diisopropylketone and CyreneTM; aprotic dipolar solvents such as DMF, dimethylacetamide (DMAc), N,N-dimethylbenzamide (DMBA), ACN, benzonitrile, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP) and dibutylformamide (DB
  • the solvent is acetonitrile, DMAc, PC, pyridine and/or DMF.
  • the amount of the solvent used in the step may be from 0.1 L to 50 L, preferably from 0.5 L to 30 L, more preferably from 1 L to 20 mL, such as 1, 2, 3, 4,
  • a catalyst may be used or not.
  • the catalyst may be any metal catalyst, preferably any Lewis acid salt, for example, those formed by metal element of Group IB, IIB and VIIIB in the Periodic Table of Elements such as element silver (Ag), cobalt (Co), copper (Cu), iron (Fe), indium (In), lanthanum (La), manganese (Mn), nickel (Ni), platinum (Pt), palladium (Pd), rhodium (Rh) and zinc (Zn); or any quaternary ammonium salt catalyst such as tetrabutylammonium chloride (TBAC), tetrabutylammonium bromide (TBAB), tetrabutylammonium iodide (TBAI), benzalkonium chloride (BAC), dimethyldioctadecyl-ammonium bromide (DDAB) and dodecyl trimethyl ammonium chloride (DTAC).
  • TBAC tetrabutylammoni
  • the catalyst examples include but are not limited to Ag 2 CO 3 , silver acetate (AgOAc), silver triflate (AgOTf), silver tungstate (Ag 2 WO 4 ), cobalt(ll) acetylacetonate (Co(acac) 2 ), Co(OAc) 2 , Cu(acac) 2 , Cu(OAc) 2 , Cu(OTf) 2 , Fe(acac) 2 , Fe(OTf) 3 , Pd(OAc) 2 , PtCI 2 , Zn(OTf) 2 , ZnCI 2 , and Zn(OAc) 2 .
  • Ag 2 CO 3 silver acetate (AgOAc), silver triflate (AgOTf), silver tungstate (Ag 2 WO 4 ), cobalt(ll) acetylacetonate (Co(acac) 2 ), Co(OAc) 2 , Cu(acac) 2 , Cu(OAc) 2 , Cu(OTf
  • the catalyst may be added into the reaction in an amount of from 0.01 mol to 0.5 mol, preferably from 0.02 mol to 0.4 mol, more preferably from 0.03 mol to 0.2 mol, such as 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19 and 0.2 mol, per 1 mol of the compound of formula (III).
  • the cyclization may be carried out at the temperature from 10°C to 200°C, preferably from 20°C to 180°C, more preferably from 50°C to 150°C such as 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 and 150°C.
  • the cyclization is carried out at from 80°C to 120°C such as 80, 85, 90, 95, 100, 105, 110, 115 and 120°C.
  • the obtained compound of formula (I) may be easily isolated by any known process, such as extraction and/or crystallization.
  • the compound of formula (III) as raw material can be synthesized by known process or according to the processes as disclosed in the examples of the present invention.
  • the present invention hereby provides a simple process for producing oxazole compounds, which saves steps, avoids salts by-products and provides high yield. Surprisingly, the inventors of the present invention discovered that the intermediate compound of formula (II) is new. Accordingly, the present invention also provides a new intermediate compound of formula (II):
  • R and X are as defined above.
  • R is H, or lower alkyl optionally substituted by one or more substituents. More preferably, R is H or Ci-C 6 alkyl optionally substituted by one or more substituents. More preferably, R is H or methyl or ethyl. The most preferably, Ri is H or methyl.
  • the compound of formula (II) can be converted to the oxazole compound of formula (I) directly in an efficient way with high yield.
  • the filter cake was loaded in a four necked round bottom flask under argon atmosphere. Butyl acetate (100 mL) was added and acetic acid (7.75 g, 129 mmol, 1.0 eq) was added dropwise in 5 mins. The reaction mixture was stirred for 30 mins at room temperature and then filtered over a paper filter (7 cm diameter). The filtrate was dried at 45°C (2 mbar) to produce a colorless oil which crystallized slowly to obtain the compound 1 (13.22 g, 98.8wt% purity, 92% yield).
  • Example 24 Under N 2 atmosphere, compound 2 (191 mg, 1.01 mmol), silver triflate (13 mg, 0.05 mmol) and Cs 2 CO 3 (488 mg, 1.50 mmol) were dissolved in DMAc (5 mL). The reaction mixture was stirred at 90°C for three hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (83 mg, 77% yield).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic and corrosive reagent, and salts by-products and has high efficiency,formula (I). Wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents.

Description

A process for preparation of oxazole compounds
Technical Field
The present invention is related to a new process for producing oxazole compounds.
Background of the Invention
Oxazole compounds represent a vast class of heterocyclic aromatic organic compounds. Oxazole compounds have become increasingly important because of biological activities and their use as intermediates for the preparation of new biological materials. The wide range of biological activities of oxazole compounds includes anti-inflammatory, analgesic, antibacterial, antifungal, hypoglycemic, antiproliferative, anti-tuberculosis, muscle relaxant and HIV inhibitor activity.
4-methyl-5-cyanooxazole is an important intermediate for producing vitamin B6. In industry, it is mainly produced by the process comprising the steps: a) ethyl acetoacetate is chlorinated to chloroethyl acetoacetate, b) chloroethyl acetoacetate is reacted with formamide to give 4-methyl-5-oxazolecarboxylic acid ethyl ester, and c) the obtained ester is dehydrated to 4-methyl-5-cyanooxazole via 4-methyl-5- oxazole carboxamide. (Werner Bonrath; Kun Peng, Qiong-Mei Zhang, Horst Pauling, Bernd-Jurgen Weimann, Ullmann's Encyclopedia of Industrial Chemistry (7th Edition) (2020)).
Figure imgf000002_0001
The above process has several disadvantages. For example, the chlorination step uses chlorine and the dehydration reaction uses phosphorus pentoxide or acetic anhydride, which are toxic or corrosive. In addition, the process produces many salts which cause environment problem.
Therefore, there is still demand of new processes for producing oxazole compounds.
Summary of the Invention
The present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic and corrosive reagents, and reduce salts by-products with high efficiency,
Figure imgf000003_0001
Figure imgf000003_0002
wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents.
The present invention also provides a new intermediate compound of formula (II), which can be used directly to produce the compound of formula (I) in an efficient way,
Figure imgf000003_0003
wherein R is as defined above, and X is halogen.
Detailed Description of the Invention
In the present invention, the term "lower alkyl" as used refers to Ci-Cw alkyl, i.e., branched or unbranched, cyclic or non-cyclic, saturated hydrocarbon comprising 1-10 carbon atoms. Preferably, the "lower alkyl" is Ci-C6 alkyl, including but not limited to methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tertbutyl, cyclobutyl, pentyl, iso-pentyl, tert-pentyl, cyclopentyl, hexyl, isohexyl, tert-hexyl, cyclohexyl, octyl, isooctyl, tert-octyl, cyclooctyl, nonyl, isononyl, tert-nonyl, cyclononyl, decyl, isodecyl, tert-decyl, cyclodecyl. More preferably, the "lower alkyl" is methyl or ethyl.
In the present invention, the term "aryl" as used refers to aromatic hydrocarbon such as phenyl, benzyl, xylyl and naphthalenyl.
In the present invention, the term "lower alkoxyl" as used refers to the structure represented by (lower alkyl)-O-, wherein the lower alkyl is as defined above.
In the present invention, the term "halo" or "halogen" as used refers to a group of elements including fluorine (F), chlorine (Cl), bromine (Br) and iodine (I), preferably refers to Cl or Br. In the present invention, the term "salt" or "salts" as used refers to any anionic and cationic complex, such as the complex formed by a cation and an anionic form of the compound of the present invention. Non-limiting examples of the cation include inorganic and organic cations, e.g., cations of the alkali and alkaline earth metals, such as sodium (Na), lithium (Li), potassium (K), calcium (Ca), magnesium (Mg), and the like, as well as ammonium, quaternary ammonium, and amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, triethylammonium and ethylammonium, and the like.
In the present invention, the term "substituent" or "substituents" as used refers to lower alkyl, lower alkoxyl, hydroxyl, halo, -NH2, -NO2, cyano and/or isocyano.
In the present invention, a compound represented by a formula or a name also cover stereoisomers thereof, including diastereomers and enantiomers, such as cis/trans-isomers or E/Z-isomers.
Particularly, the present invention provides a process for producing a compound of formula (I), comprising the steps: a) Halogenating a compound of formula (III) or a salt thereof to produce a compound of formula (II); and
Figure imgf000004_0001
b) Cyclizing the compound of formula (II) to obtain the compound of formula (I),
Figure imgf000004_0002
wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents; and X is halogen. Preferably, R is H, or lower alkyl optionally substituted by one or more substituents. More preferably, R is H or Ci-C6 alkyl optionally substituted by one or more substituents. Most preferably, R is H or methyl or ethyl. The most preferably, Ri is H or methyl.
In the present invention, the salt of the compound of formula (III) may be a compound of formula (III') or its tautomeric form of formula (III"):
Figure imgf000005_0001
wherein R is as defined above, and Y is a metal element such as alkali metal elements such as lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and cesium (Cs); or alkaline-earth metal elements such as beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr) and barium (Ba); and iron (ll/lll), nickel (Ni) and cobalt (Co). Preferably, Y is Na or K.
In the step a) of the process of the present invention, the compound of formula (III) or a salt thereof may be halogenated by a halogen or a halogen-containing compound.
In the present invention, the halogen-containing compound may be a halide salt such as alkali metal salts, alkaline-earth metal salts or quaternary ammonium salts of a halogen. Examples of the halide salt include but are not limited to KF, NaF, NaBr, KBr, MgBr2, NaCI, KCI, RbCI, CuCI2, LiCI, AgCI, CaCI2, KI, Agl2, tetrabutylammonium chloride (TBAC), tetrabutylammonium bromide (TBAB), tetrabutylammonium iodide (TBAI), benzalkonium chloride (BAC), dimethyldioctadecyl-ammonium bromide (DDAB) and dodecyl trimethyl ammonium chloride (DTAC). Preferably, the halide is NaBr and KBr.
In the present invention, the halogen-containing compound may also be a halogen-containing organic compound. Example of the suitable halogen-containing organic compound includes but is not limited to N-Bromosuccinimide (NBS), N-Chlorosuccinimide (NCS), N-lodosuccinimide (NIS), halo hydantoin such as dibromohydantoin, dichlorohydantoin and diiodohydantoin, and halo cyanuric acid such as cyanuric fluoride, trichloroisocyanuric acid, tribromoisocyanuric acid and triiodoisocyanuric acid. In an embodiment of the present invention, the compound of formula (III) or a salt thereof is halogenated by a halogen, preferably in the presence of a base. The base may be any organic or inorganic base or mixture thereof which can neutralize hydrogen halide generated in the reaction. Example of the base includes but is not limited to as KOH, NaOH, Na2CO3, K2CO3, NaNH2, KF/AI2O3, potassium tert-butoxide (t- BuOK), sodium t-pentyloxide and the others. Preferably, the base is K2CO3. The halogen may be added into the reaction in an amount of from 0.1 mol to 2 mol, preferably from 0.2 mol to 1.5 mol, more preferably from 0.3 mol to 1 mol, such as 0.3, 0.35, 0.4, 0.45. 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 and 1 mol, per 1 mol of the compound of formula (III). The base may be added into the reaction in an amount of from 0.1 mol to 10 mol, preferably from 0.5 mol to 8 mol, more preferably from 1.0 mol to 5 mol, such as 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 and 5 mol, per 1 mol of the compound of formula (III).
In a preferable embodiment of the present invention, the compound of formula (III) or a salt thereof is halogenated by a halide salt as defined above in the presence of an oxidant. The oxidant may be any oxidant known in the art. A good example of the oxidant includes but is not limited to peroxides such as hydrogen peroxide, peroxyformic acid, peroxyacetic acid, peroxypropionic acid, peroxide benzenesulfonyl acid, peroxide p-toluenesulfonyl acid and peroxide methylsulfonyl acid. The halide salt may be added into the reaction in an amount of from 0.5 mol to 5.0 mol, preferably from 0.8 mol to 3.0 mol, more preferably from 1.0 mol to 2.0 mol, such as 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 2.0 mol, per 1 mol of the compound of formula (III). The oxidant may be added into the reaction in an amount of from 1 mol to 10 mol, preferably from 2 mol to 8 mol, more preferably from 0.5 mol to 5 mol, preferably from 1.0 mol to 4.0 mol, more preferably from 1.5 mol to 3.0 mol, such as 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3.0 mol, per 1 mol of the compound of formula (III).
In the embodiment that the compound of formula (III) or a salt thereof is halogenated by a halide salt, the halogenation is preferably carried out in the presence of an acid. The acid may be any organic acid such as aliphatic acid or aromatic acid, or inorganic acid. Examples of the organic acid include but are not limited to lactic acid, acetic acid, formic acid, propanoic acid, butanoic acid, benzoic acid, p-methyl benzoic acid, citric acid, oxalic acid, malic acid and tartaric acid. Examples of the inorganic acid include but are not limited to hydrochloric acid (HCI), nitric acid (HNO3), phosphoric acid (H3PO4), sulfuric acid (H2SO4), sulfurous acid (H2SO3), carbonic acid (H2CO3), hydrofluoric acid (HF) and hydrobromic acid (HBr). Preferably, the acid is organic acid. More preferably, the acid is formic acid, acetic acid, benzoic acid or 4- methylbenzoic acid. The acid may be added into the reaction in an amount of from 0.1 mol to 10 mol, preferably from 0.5 mol to 8.0 mol, more preferably from 1 mol to 5 mol, such as 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 5.0 mol, per 1 mol of the compound of formula (III). In such an embodiment, a pH modifier such as sodium dihydrogen phosphate (NaH2PO4) and disodium hydrogen phosphate (Na2HPO4) may be added to maintain the pH value of the reaction mixture at from 3.5 to 6.0, preferably from 4.0 to 5.5.
In a more preferable embodiment, the compound of formula (III) or a salt thereof is halogenated by a halogen-containing organic compound such as N-Bromosuccinimide (NBS), N-Chlorosuccinimide (NCS), N- lodosuccinimide (NIS), dibromohydantoin, dichlorohydantoin, diiodohydantoin, cyanuric fluoride, trichloroisocyanuric acid, tribromoisocyanuric acid and triiodoisocyanuric acid. The halogen-containing organic compound may be added into the reaction in an amount of from 0.1 mol to 5 mol, preferablyfrom 0.2 mol to 3 mol, more preferably from 0.3 mol to 2 mol, such as 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 2 mol, per 1 mol of the compound of formula (III).
In the step a) of the process of the present invention, one or more solvents may be used. Examples of the suitable solvents include but are not limited to esters such as ethyl acetate, propyl acetate and butyl acetate, alcohols such as methanol and ethanol, nitriles such as acetonitrile (ACN) and benzonitrile, and benzene, toluene, chlorobenzene, xylene, dimethylformamide (DMF), dichloromethane (DCM), water and others that are common-used as a solvent in the field. Preferably water or butyl acetate or DCM is used as the solvent. More preferably two or more solvents which are immiscible are used. The most preferably, water and butyl acetate or DCM are used as the solvents.
In the step a) of the process of the present invention, the solvents may be added into the reaction in an amount of from 0.1 L to 20 L, preferably from 0.2 Lto 15 L, more preferably from 0.5 L to 10 L, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 and 10 L, per 1 mol of the compound of formula (III).
In the step a) of the process of the present invention, a catalyst may be used. The catalyst may be any metal catalyst. Examples of the suitable catalyst include but are not limited to Cu(OAc)2, CuCI2, FeCI3, CoCI2, NH4VO3, Na2WO4, and heteropoly acid such as phosphotungstic acid, silicoptungstigacid (H4PWI2O40 (hydrate) and phosphomolybdic acid, and hydrate thereof. More preferably, the catalyst is Cu(OAc)2, Na2WO4»2H2O, FeCI3»6H2O, CoCI2, CuCI2»2H2O and phosphotungstic acid hydrate. The catalyst may be added into the reaction in an amount of from 0.0001 mol to 0.5 mol, preferably from 0.0005 mol to 0.4 mol, more preferably from 0.001 mol to 0.3 mol, such as 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25 and 0.3 mol, per 1 mol of the compound of formula (III).
In the process of the present invention, the halogenation of the step a) may be carried out at room temperature. The obtained compound of formula (III) may be directly used for the next step or easily isolated by any known process, such as evaporation, extraction and/or crystallization, for use in the next step.
In the step b) of the process of the present invention, the cyclization may be achieved by treating the compound of formula (II) with one or more bases. The suitable bases may be strong bases, including but not limited to organic base such as l,5-diazabicyclo(4.3.0)non-5-ene (DBN), l,8-diazabicyclo[5.4.0]undec- 7-ene (DBU), 1,1,3,3-tetramethylguanidine (TMG), and alkoxide such as potassium tert-butoxide (tBuOK) and sodium t-pentyloxide; and inorganic base such as NaH, KOH, NaOH, Na2CO3, K2CO3, KF/AI2O3, Cs2CO3 and NaNH2, and mixture thereof. Preferably the base is NaH, DBN, DBU, TMG, Cs2CO3, NaNH2, or K2CO3, or mixture thereof. The amount of the bases used in the step may be from 0.1 mol to 10 mol, preferably from 0.5 mol to 8 mol, more preferably from 1 mole to 5 moles such as 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 and 10 moles, per 1 mole of the compound of formula (II).
In the step b) of the process of the present invention, one or more solvents are preferably used. Examples of the solvents suitable for the step b) of the process include but are not limited to alcohol such as n- butanol and 2,2,2-trifluorethanol (TFE); ether such as methyl tert-butyl ether (MTBE), 2-methyl tetrahydrofuran (Me-THF) and 1,4-dioxane; ester such as ethyl acetate, butylacetate, dimethyl carbonate (DMC) and propylene carbonate (PC); ketone such as cyclohexanone, diisopropylketone and Cyrene™; aprotic dipolar solvents such as DMF, dimethylacetamide (DMAc), N,N-dimethylbenzamide (DMBA), ACN, benzonitrile, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP) and dibutylformamide (DBF); halide solvents such as dichloroethane (DCE), DCM and chloroform; organic bases such as pyridine and quinoline; deep eutectic solvent such as choline chloride (ChCI)/urea, AcChCl/urea and ZnCI2/urea; and ionic liquid such as l-ethyl-3-methylimidazolium tetrafluoroborate ([emim[[BF4]), l-butyl-3- methylimidazolium chloride ([bmim][CI]) and 1-butylpyridinium chloride ([bpy][CI]). Preferably the solvent is acetonitrile, DMAc, PC, pyridine and/or DMF. The amount of the solvent used in the step may be from 0.1 L to 50 L, preferably from 0.5 L to 30 L, more preferably from 1 L to 20 mL, such as 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 L, per 1 mol of the compound of formula (II).
In the step b) of the process of the present invention, a catalyst may be used or not. The catalyst may be any metal catalyst, preferably any Lewis acid salt, for example, those formed by metal element of Group IB, IIB and VIIIB in the Periodic Table of Elements such as element silver (Ag), cobalt (Co), copper (Cu), iron (Fe), indium (In), lanthanum (La), manganese (Mn), nickel (Ni), platinum (Pt), palladium (Pd), rhodium (Rh) and zinc (Zn); or any quaternary ammonium salt catalyst such as tetrabutylammonium chloride (TBAC), tetrabutylammonium bromide (TBAB), tetrabutylammonium iodide (TBAI), benzalkonium chloride (BAC), dimethyldioctadecyl-ammonium bromide (DDAB) and dodecyl trimethyl ammonium chloride (DTAC). Examples of the catalyst include but are not limited to Ag2CO3, silver acetate (AgOAc), silver triflate (AgOTf), silver tungstate (Ag2WO4), cobalt(ll) acetylacetonate (Co(acac)2), Co(OAc)2, Cu(acac)2, Cu(OAc)2, Cu(OTf)2, Fe(acac)2, Fe(OTf)3, Pd(OAc)2, PtCI2, Zn(OTf)2, ZnCI2, and Zn(OAc)2. The catalyst may be added into the reaction in an amount of from 0.01 mol to 0.5 mol, preferably from 0.02 mol to 0.4 mol, more preferably from 0.03 mol to 0.2 mol, such as 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19 and 0.2 mol, per 1 mol of the compound of formula (III).
In the step b) of the process of the present invention, the cyclization may be carried out at the temperature from 10°C to 200°C, preferably from 20°C to 180°C, more preferably from 50°C to 150°C such as 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 and 150°C. Preferably, the cyclization is carried out at from 80°C to 120°C such as 80, 85, 90, 95, 100, 105, 110, 115 and 120°C.
The obtained compound of formula (I) may be easily isolated by any known process, such as extraction and/or crystallization.
The compound of formula (III) as raw material can be synthesized by known process or according to the processes as disclosed in the examples of the present invention.
The present invention hereby provides a simple process for producing oxazole compounds, which saves steps, avoids salts by-products and provides high yield. Surprisingly, the inventors of the present invention discovered that the intermediate compound of formula (II) is new. Accordingly, the present invention also provides a new intermediate compound of formula (II):
Figure imgf000010_0001
Wherein R and X are as defined above.
Preferably, R is H, or lower alkyl optionally substituted by one or more substituents. More preferably, R is H or Ci-C6 alkyl optionally substituted by one or more substituents. More preferably, R is H or methyl or ethyl. The most preferably, Ri is H or methyl.
The compound of formula (II) can be converted to the oxazole compound of formula (I) directly in an efficient way with high yield.
The present invention will be further illustrated by the following examples.
Examples
Example 1
Figure imgf000010_0002
A dried four necked round bottom flask was charged with liquid ammonia (50 mL, 2.05 mol, 16 eq). After the flask was flushed with argon, iron nitrate nonahydrate (35 mg, 0.087 mmol, 0.00067 eq) was added. Then sodium (2.96 g, 129 mmol, 1.0 eq) was added and stirred for 30 mins at -40°C to -50°C. At the same temperature anhydrous acetonitrile (11.65 g, 283 mmol, 2.2 eq) was added dropwise in 15 mins and anhydrous toluene (40 mL) was added immediately. The reaction mixture was warmed to room temperature in 1 hour and stirred for additional 1 hour to obtain a grey suspension. Ethyl formate (10.71 g, 142 mmol, 1.1 eq) dissolved in anhydrous toluene (20 mL) was added dropwise in 20 mins. The reaction mixture was stirred overnight to obtain a grey and thick suspension. TBME (100 mL) was added and the mixture was filtrated over a paper filter (7 cm diameter) to obtain a filter cake.
The filter cake was loaded in a four necked round bottom flask under argon atmosphere. Butyl acetate (100 mL) was added and acetic acid (7.75 g, 129 mmol, 1.0 eq) was added dropwise in 5 mins. The reaction mixture was stirred for 30 mins at room temperature and then filtered over a paper filter (7 cm diameter). The filtrate was dried at 45°C (2 mbar) to produce a colorless oil which crystallized slowly to obtain the compound 1 (13.22 g, 98.8wt% purity, 92% yield).
2H NMR of Z-isomer of compound 4 (400 MHz, DMSO) 6 (ppm): 10.20 (1H), 8.43 (1H), 4.90 (1H), 2.15 (3H). 2H NMR of £-isomer of compound 4 (400 MHz, DMSO) 6 (ppm): 10.40 (1H), 8.81 - 8.14 (1H), 6.37 - 4.78 (1H), 2.39 -1.97 (3H).
Example 2
Figure imgf000011_0001
To a suspension of compound 1 (227 mg, 2.0 mmol), NaBr (249.6 mg, 2.86 mmol), Cu(OAc)z (22 mg, 0.12 mmol) and acetic acid (240 mg, 4.0 mmol) in DCM (1 mL), an aqueous solution of hydrogen peroxide (600 mg, 28% w/w, 4.94 mmol) was added dropwise in 2 hours and the reaction mixture was stirred for another 10 hours at room temperature. The organic phase was collected, and the aqueous phase was extracted with ethyl acetate. The combined organic phase was analyzed by HPLC to give 354.5 mg compound 2 with 93.8% yield.
Example 3
Figure imgf000012_0001
To a suspension of the compound 1 (227 mg, 2.0 mmol), NaBr (312 mg, 3.0 mmol), Na2WO4»2H2O (2.2 mg, 0.006 mmol) and acetic acid (240 mg, 4.0 mmol) in n-butyl acetate (1.5 mL) and H2O (0.9 mL), an aqueous solution of hydrogen peroxide (600 mg, 17% w/w, 3.0 mmol) was added dropwise in 2 hours and the reaction mixture was stirred for another 6 hours at room temperature. The organic phase was collected, and the aqueous phase was extracted with n-butyl acetate. The combined organic phase was analyzed by HPLC to give 359.1 mg compound 2 with 95.0 % yield.
Example 4
Figure imgf000012_0002
To a suspension of the compound 1 (113 mg, 1.0 mmol), NaBr (156 mg, 1.5 mmol), Na2WO4»2H2O (1.1 mg, 0.003 mmol) and p-methylbenzic acid (272 mg, 2.0 mmol) in n-butyl acetate (1.5 mL) and H2O (0.9 mL), an aqueous solution of hydrogen peroxide (300 mg, 17% w/w, 1.5 mmol) was added dropwise in 2 hours and the reaction mixture was stirred for another 6 hours at room temperature. The organic phase was collected, and the aqueous phase was extracted with n-butyl acetate. The combined organic phase was analyzed by HPLC to give 109.8 mg compound 2 with 58.1 % yield.
Example 5
Figure imgf000012_0003
To a suspension of the compound 1 (12.25 g, 0.1 mol), NaBr (15.6 g, 1.5 mol) and Na2WO4»2H2O (0.11 g, 0.3 mmol) in n-butyl acetate (75 mL) and H2O (32.0 mL), an aqueous solution of hydrogen peroxide (17.0 g, 30% w/w, 0.15 mol) was added dropwise in 4 hours at 25°C and CO2 was bubbled into aqueous phase at the same time. The reaction mixture was hold for another 2 hours. The organic phase was collected, and the aqueous phase was extracted with n-butyl acetate. The combined organic phase was analyzed by HPLC to give compound 2 with 75 % yield.
Example 6
Figure imgf000013_0001
To a suspension of the compound 1 (12.25 g, 0.1 mol), NaBr (7.8 g, 0.075 mol), Na2WO4»2H2O (0.11 g, 0.3 mmol) and NaH2PO4 (12.0 g, 0.1 mol) in n-butyl acetate (75 mL) and H2O (32.0 mL), an aqueous solution of hydrogen peroxide (17.0 g, 30% w/w, 0.15 mol) and aqueous HBr (16.88 g, 0.10 mol) were added simultaneously dropwise in 4 hours at 25°C. The reaction mixture was hold for another 1 hour. The organic phase was collected, and the aqueous phase was extracted with n-butyl acetate. The combined organic phase was analyzed by HPLC to give compound 2 with 89.8 % yield.
Example 7
Figure imgf000013_0002
To a suspension of the compound 1 (227 mg, 2.0 mmol), NaBr (249.6 mg, 2.86 mmol), phosphotungstic acid hydrate (10 mg, 0.002 mmol) and acetic acid (240 mg, 4.0 mmol) in H2O (5.4 mL), an aqueous solution of hydrogen peroxide (600 mg, 17% w/w, 3.0 mmol) was added dropwise in 2 hours and the reaction mixture was stirred for another 12 hours at room temperature. The reaction mixture was extracted by ethyl acetate (3x6 mL). The organic phase was collected, and the aqueous phase was extracted with ethyl acetate. The combined organic phase was analyzed by HPLC to give 372.7 mg compound 2 with 98.6 % yield.
Example 8
Figure imgf000014_0001
To a suspension of the compound 1 (227 mg, 2.0 mmol), KBr (357 mg, 3.0 mmol), Na2WO4.2H2O (2.2 mg, 0.006 mmol) and acetic acid (240 mg, 4.0 mmol) in n-butyl acetate (1.5 mL) and H2O (0.9 mL) was added dropwise an aqueous solution of hydrogen peroxide (600 mg, 17% w/w, 3.0 mmol) in water in 2 hours and hold for another 6 hours at room temperature. The organic phase was collected, and the aqueous phase was extracted with n-butyl acetate. The combined organic phase was analyzed by HPLC to give the compound 2 (360.2 mg, 95.3 % yield)
Example 9
Figure imgf000014_0002
To a suspension of the compound 1 (227 mg, 2.0 mmol) and K2CO3 (552 mg, 4 mmol) in DMF (3 mL), Br2 (178 mg, 1.11 mmol) in DMF (1 mL) was added in 30 minutes at room temperature and the reaction mixture was stirred for one hour at the same temperature. The mixture was filtered off and the filtrate was analyzed by HPLC to give compound 2 (273 mg, 70.1% yield).
Example 10
Figure imgf000014_0003
2
To a suspension of the compound 1 (2.27 g, 20.0 mmol) in DMF (50 mL) was added NBS (2.19 g, 24.6 mmol) in 4 portions in 30 minutes at room temperature and hold for another 2 hours. The reaction solution was washed with 20.0 g water, organic phase was analyzed by HPLC to give the compound 2 (3.60 g, 95.1 % yield). Example 11
Figure imgf000015_0001
Dibromohydantoin
To a suspension of the compound 1 (56.0 mg, 0.5 mmol) in DCM (1 mL) was added dibromohydantoin (86 g, 0.3 mmol) at room temperature and hold for 10 minutes. DCM (5 mL) and H2O (3 mL) were added to the reaction mixture and stirred for another 10 minutes. After separation, the organic phase was analyzed by HPLC to give the compound 2 (90.6 mg, 95.9% yield).
Example 12
Figure imgf000015_0002
Trichloroisocyanuric acid 4
To a suspension of the compound 1 (2.27 g 20.0 mmol) in DCM (50 mL) was added trichloroisocyanuric acid (2.37 g, 10.0 mmol) in 3 portions in 30 minutes at room temperature and hold for another 2 hours, the reaction solution was washed with 20.0 g water. Organic phase was analyzed by HPLC to give the compound 4 (2.20 g, 75.4 % yield).
Example 13
Figure imgf000015_0003
To a suspension of the compound 1 (227 mg, 2.0 mmol), NaBr (312 mg, 3.0 mmol), the catalysts as listed in below table and acetic acid (240 mg, 4.0 mmol) in n-butyl acetate (1.5 mL) and H2O (0.9 mL), an aqueous solution of hydrogen peroxide (600 mg, 17% w/w, 3.0 mmol) was added dropwise in 2 hours and the reaction mixture was stirred for another 6 hours at room temperature. The organic phase was collected, and the aqueous phase was extracted with n-butyl acetate. The combined organic phase was analyzed by
HPLC to give compound 2.
Figure imgf000016_0003
Example 14
Figure imgf000016_0001
Under N2 atmosphere, to a solution of compound 2 (191 mg, 1.01 mmol) in ACN (10 mL), DBU (387 uL, 2.60 mmol) was added. The reaction mixture was stirred at 70°C for two hours. After reaction completed, the solvent was removed by rotational evaporation. The yield of compound 3 was determined by quantitative HPLC (95 mg, 87% yield).
Example 15
Figure imgf000016_0002
Under N2 atmosphere, to a solution of compound 2 (380 mg, 2.00 mmol) in ACN (2 mL), DBN (372 mg, 3.0 mmol) was added. The reaction mixture was stirred at 80°C for 30 mins. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (36 mg, 33% yield). Example 16
Figure imgf000017_0001
Under N2 atmosphere, to a solution of compound 2 (191 mg, 1.01 mmol) in DMF (10 mL), DBU (387 uL, 2.60 mmol) was added. The reaction mixture was stirred at 70°C for two hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (93 mg, 86% yield).
Example 17
Figure imgf000017_0002
Under N2 atmosphere, to a solution of compound 2 (191 mg, 1.01 mmol) in pyridine (10 mL), DBU (387 uL, 2.60 mmol) was added. The reaction mixture was stirred at 70°C for two hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (82 mg, 75% yield).
Example 18
Figure imgf000017_0003
Under N2 atmosphere, to a solution of compound 2 (191 mg, 1.01 mmol) in PC (10 mL), DBU (387 uL, 2.60 mmol) was added. The reaction mixture was stirred at 80°C for two hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (84 mg, 77% yield). Example 19
Figure imgf000018_0001
Under N2 atmosphere, to a solution of compound 2 (191 mg, 1.01 mmol) in DMAc (10 mL), TMG (288 mg, 2.5 mmol) was added. The reaction mixture was stirred at 75°C for two hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (87 mg, 80% yield).
Example 20
Figure imgf000018_0002
Under N2 atmosphere, compound 2 (191 mg, 1.01 mmol) and K2CO3 (621 mg, 4.50 mmol) were dissolved in DMAc (2 mL). The reaction mixture was stirred at 90°C for four hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (76 mg, 70% yield).
Example 21
Figure imgf000018_0003
Under N2 atmosphere, compound 2 (191 mg, 1.01 mmol) and Cs2CO3 (488 mg, 1.50 mmol) were dissolved in DMAc (5 mL). The reaction mixture was stirred at 90°C for three hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (65 mg, 60% yield).
Example 22
Figure imgf000019_0001
Under N2 atmosphere, compound 2 (191 mg, 1.01 mmol) and NaNH2 (55 mg, 1.38 mmol) were dissolved in DMAc (10 mL). The reaction mixture was stirred at 70°C for four hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (78 mg, 72% yield).
Example 23
Figure imgf000019_0002
Under N2 atmosphere, to a solution of compound 2 (191 mg, 1.01 mmol) and zinc triflate (38 mg, 0.1 mmol) in ACN (10 mL), DBU (387 ul, 2.60 mmol) was added. The reaction mixture was stirred at 70°C for two hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (101 mg, 93% yield).
Example 24
Figure imgf000019_0003
Under N2 atmosphere, compound 2 (191 mg, 1.01 mmol), silver triflate (13 mg, 0.05 mmol) and Cs2CO3 (488 mg, 1.50 mmol) were dissolved in DMAc (5 mL). The reaction mixture was stirred at 90°C for three hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (83 mg, 77% yield).
Example 25
Figure imgf000020_0001
Under N2 atmosphere, to a solution of DBU (11.0 ml, 72.2 mmol) and zinc acetate (0.27 g, 1.48 mmol) in ACN (25 mL), compound 2 (9.10 g, 48.1 mmol) dissolved in ACN (25 mL) was dosed in 2 hours. The reaction mixture was stirred at 90°C in oil bath during dosing and hold for additional two hours. After reaction completed, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (4.72 g, 91% yield).
Example 26
Figure imgf000020_0002
Under N2 atmosphere, NaH (80mg, 60%, 2.0 mmol) was add to a solution of compound 2 (387 mg 2.0 mmol) in DMF (2 mL) and stirred at room temperature for 5 minutes, then DBU (60.8 mg, 0.4 mmol) was added and stirred at 100°C for another 5 minutes, the reaction mixture was cooled to room temperature. The yield of compound 3 was determined by quantitative HPLC (173 mg, 80 % yield).

Claims

Claims
1. A process for producing a compound of formula (I), comprising the steps: a) Halogenating a compound of formula (III) or a salt thereof to produce a compound of formula (II); and
Figure imgf000021_0001
b) Cyclizing the compound of formula (II) to obtain the compound of formula (I),
Figure imgf000021_0002
wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents; and X is halogen.
2. The process of claim 1, wherein R is H or Ci-C6 alkyl optionally substituted by one or more substituents.
3. The process of claim 1, wherein R is H or methyl or ethyl.
4. The process of claim 1, wherein the salt of the compound of formula (III) is a compound of formula (III') or its tautomeric form of formula (III"):
Figure imgf000021_0003
(HI’) (HI") wherein R is defined as claims 1-3, and Y is a metal element such as alkali metal elements such as lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and cesium (Cs); or alkaline-earth metal elements such as beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr) and barium (Ba); and iron (ll/lll), nickel (Ni) and cobalt (Co).
5. The process of any one of claims 1-4, wherein, in the step a), the compound of formula (III) or a salt thereof is halogenated by a halogen or a halogen-containing compound.
6. The process of claim 5, wherein the halogen-containing compound is a halide salt such as alkali metal salts, alkaline-earth metal salts or quaternary ammonium salt of a halogen, including but not limited to KF, NaF, NaBr, KBr, MgBr2, NaCI, KCI, RbCI, CuCI2, LiCI, AgCI, CaCI2, KI, Agl2, tetrabutylammonium chloride (TBAC), tetrabutylammonium bromide (TBAB), tetrabutylammonium iodide (TBAI), benzalkonium chloride (BAC), dimethyldioctadecyl-ammonium bromide (DDAB), dodecyl trimethyl ammonium chloride (DTAC).
7. The process of claim 5, wherein the halogen-containing compound is a halogen-containing organic compound, including but not limited to N-Bromosuccinimide (NBS), N-Chlorosuccinimide (NCS), N- lodosuccinimide (N IS), halo hydantoin such as dibromohydantoin, dichlorohydantoin and diiodohydantoin, and halo cyanuric acid such as cyanuric fluoride, trichloroisocyanuric acid, tribromoisocyanuric acid and triiodoisocyanuric acid.
8. The process of any one of claims 1-4, wherein the compound of formula (III) or a salt thereof is halogenated by a halogen in the presence of a base.
9. The process of claim 8, wherein the base is any organic or inorganic base selected from the group consisting of KOH, NaOH, Na2CO3, K2CO3, NaNH2, KF/AI2O3, potassium tert-butoxide (t-BuOK) and sodium t-pentyloxide, or mixture thereof.
10. The process of any one of claims 1-4, wherein the compound of formula (III) or a salt thereof is halogenated by a halide salt in the presence of an oxidant.
11. The process of claim 10, wherein the oxidant is selected from the group consisting of hydrogen peroxide, peroxyformic acid, peroxyacetic acid, peroxypropionic acid, peroxide benzenesulfonyl acid, peroxide p-toluenesulfonyl acid and peroxide methylsulfonyl acid.
12. The process of claim 10, wherein the halogenation is carried out in the presence of an acid.
13. The process of claim 13, wherein the acid is any organic acid such as aliphatic acid or aromatic acid, including but not limited to lactic acid, acetic acid, formic acid, propanoic acid, butanoic acid, benzoic acid, 4-methylbenzoic acid, citric acid, oxalic acid, malic acid and tartaric acid; or any inorganic acid, including but not limited to hydrochloric acid (HCI), nitric acid (HNO3), phosphoric acid (H3PO4), sulfuric acid (H2SO4), sulfurous acid (H2SO3), carbonic acid (H2CO3), hydrofluoric acid (HF) and hydrobromic acid (HBr).
14. The process of any one of claims 1-13, wherein one or more solvents are used in the step a).
15. The process of claim 14, wherein the solvents are selected from the group consisting of esters such as ethyl acetate, propyl acetate and butyl acetate, alcohols such as methanol and ethanol, nitriles such as acetonitrile (ACN) and benzonitrile, and benzene, toluene, chlorobenzene, xylene, dimethylformamide (DMF), dichloromethane (DCM), and water.
16. The process of claim 14, wherein two or more solvents such as DCM and water are used.
17. The process of any one of claims 1-16, wherein a catalyst is used in the step a).
18. The process of any one of claims 17, wherein the catalyst is any metal catalyst including but not limited to Cu(OAc)2, CuCI2, FeCI3, CoCI2, NH4VO3, Na2WO4, and heteropoly acid such as phosphotungstic acid, silicoptungstigacid (H4RWI2O40 (hydrate) and phosphomolybdic acid, and hydrate thereof, preferably is FeCI3»6H2O, CoCI2, CuCI2»2H2O or phosphotungstic acid hydrate.
19. The process of any one of claims 1-18, wherein, in the step b), the cyclization is achieved by treating the compound of formula (II) with one or more bases.
20. The process of claim 19, wherein the bases are strong bases, including but not limited to organic base such as l,5-diazabicyclo(4.3.0)non-5-ene (DBN), l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1, 1,3,3- tetramethylguanidine (TMG), and alkoxide such as potassium tert-butoxide (tBuOK) and sodium t- pentyloxide; and inorganic base such as NaH, KOH, NaOH, Na2CO3, K2CO3 and NaNH2, and mixture thereof.
21. The process of any one of claims 1-18, wherein one or more solvents are used in the step b).
22. The process of claim 21, wherein the solvents are selected from the group consisting of alcohol such as n-butanol and 2,2,2-trifluorethanol (TFE); ether such as methyl tert-butyl ether (MTBE), 2-methyl tetrahydrofuran (Me-THF) and 1,4-dioxane; ester such as ethyl acetate, butylacetate, dimethyl carbonate (DMC) and propylene carbonate (PC); ketone such as cyclohexanone, diisopropylketone and Cyrene™; aprotic dipolar solvents such as DMF, dimethylacetamide (DMAc), N,N-dimethylbenzamide (DMBA), ACN, benzonitrile, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP) and dibutylformamide (DBF); halide solvents such as dichloroethane (DCE), DCM, chloroform; organic bases such as pyridine and quinoline; deep eutectic solvent such as ChCl/urea, AcChCl/urea and ZnCI2/urea; and ionic liquid such as [emim[[BF4], [bmim][CI] and [bpy][CI].
23. The process of any one of claims 1-18, wherein a catalyst is used in the step b).
24. The process of claim 23, wherein the catalyst is any metal catalyst, preferably any Lewis acid salt, for example, those formed by metal element of Group IB, 11 B and VI I IB in the Periodic Table of Elements such as element Silver, Cobalt, Copper, Iron, Indium, Lanthanum, Manganese, Nickel, Platinum, Palladium, Rhodium or Zinc, including but not limited to Ag2CO3, Silver acetate, Silver triflate, silver tungstate, Cobalt(ll) acetylacetonate, Co(OAc)2, Cu(acac)2, Cu(OAc)2, Cu(OTf)2, Fe(acac)2, Fe(OTf)3, Pd(OAc)2, PtCI2, Zn(OTf)2, ZnCI2 and Zn(OAc)2.
25. The process of any one of the above claims, wherein the cyclization in the step b) is carried out at the temperature from 10°C to 200°C, preferably from 20°C to 180°C, more preferably from 50°C to 150°C such as 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 and 150°C.
26. A compound of formula (II):
Figure imgf000024_0001
wherein R is H, or lower alkyl or aryl optionally substituted by one or more substituents; and X is halogen.
PCT/EP2021/070913 2020-08-06 2021-07-27 A process for preparation of oxazole compounds WO2022028941A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21755385.8A EP4192820A1 (en) 2020-08-06 2021-07-27 A process for preparation of oxazole compounds
CN202180057147.2A CN116075498A (en) 2020-08-06 2021-07-27 Process for preparing oxazole compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020107370 2020-08-06
CNPCT/CN2020/107370 2020-08-06

Publications (1)

Publication Number Publication Date
WO2022028941A1 true WO2022028941A1 (en) 2022-02-10

Family

ID=77358212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/070913 WO2022028941A1 (en) 2020-08-06 2021-07-27 A process for preparation of oxazole compounds

Country Status (3)

Country Link
EP (1) EP4192820A1 (en)
CN (1) CN116075498A (en)
WO (1) WO2022028941A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023052103A1 (en) * 2021-09-28 2023-04-06 Dsm Ip Assets B.V. A new intermediate for preparation of oxazole compounds
WO2023052104A1 (en) * 2021-09-28 2023-04-06 Dsm Ip Assets B.V. A process for preparation of oxazole compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502212A (en) * 1993-02-25 1996-03-26 Hoffmann-La Roche Inc. Process for the manufacture of 5-cyano-4-lower alkyl-oxazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502212A (en) * 1993-02-25 1996-03-26 Hoffmann-La Roche Inc. Process for the manufacture of 5-cyano-4-lower alkyl-oxazoles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU XIN ET AL: "Direct [beta]-Acyloxylation of Enamines via PhIO-Mediated Intermolecular Oxidative C-O Bond Formation and Its Application to the Synthesis of Oxazoles", ORGANIC LETTERS, vol. 14, no. 21, 2 November 2012 (2012-11-02), US, pages 5480 - 5483, XP055837609, ISSN: 1523-7060, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/ol3025583> DOI: 10.1021/ol3025583 *
WERNER BONRATHKUN PENGQIONG-MEI ZHANGHORST PAULINGBERND-JURGEN WEIMANN: "Ullmann's Encyclopedia of Industrial Chemistry", 2020

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023052103A1 (en) * 2021-09-28 2023-04-06 Dsm Ip Assets B.V. A new intermediate for preparation of oxazole compounds
WO2023052104A1 (en) * 2021-09-28 2023-04-06 Dsm Ip Assets B.V. A process for preparation of oxazole compounds

Also Published As

Publication number Publication date
EP4192820A1 (en) 2023-06-14
CN116075498A (en) 2023-05-05

Similar Documents

Publication Publication Date Title
WO2022028941A1 (en) A process for preparation of oxazole compounds
DE60217126T2 (en) PREPARATION OF AMINO-PRIMIDINE COMPOUNDS
WO2006016510A1 (en) Method for producing 2-amino-5-iodobenzoic acid
US10377703B2 (en) Method for producing 4-(trifluoromethylsulfonyl)phenol compound
RU2402528C2 (en) Improved method for synthesis of nitroisourea derivatives
EP4136066A1 (en) A process for preparation of substituted enamine compounds
JP2022552273A (en) Method for preparing 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid
WO2018065316A1 (en) Method for producing cyclopropyl-substituted acetophenones
US5352843A (en) Preparation of β-naphthyl benzyl ether
CA2753644C (en) A process for the eco-friendly preparation of 3, 5-dibromo-4-hydroxybenzonitrile
WO2023052104A1 (en) A process for preparation of oxazole compounds
JP4138067B2 (en) Method for producing methine derivative
AU767379B2 (en) Chemical processes
JP4275348B2 (en) Method for producing (dioxolenon-4-yl) methyl ester derivative
WO2023052103A1 (en) A new intermediate for preparation of oxazole compounds
EP1003718B1 (en) Method for the production of n-(5-amino-2-cyano-4-fluoro-phenyl)-sulphonamides
EP0994099B1 (en) Process for preparing 4-cyano-3-nitrobenzotrifluoride from 3-bromo-4-cyanobenzotrifluoride in the presence of catalytic cuprous cyanide and a phase transfer catalyst.
JP7453365B2 (en) High purity N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide and its production method
CN110655491B (en) Simple preparation method of 2-aminopyrimidine-5-formic ether
EP4366771A1 (en) A process for the preparation of pure 2-nitro-4-methylsulfonyl benzoic acid
EP3368510B1 (en) Method for the preparation of 2-alkyl-4-trifluormethyl-3-alkylsulfonyl benzoic acids
JP3581721B2 (en) Method for producing N-substituted-3-iodopropioamide and its synthetic intermediate
CN112204015A (en) Process for preparing halogenated N-arylpyrazoles
EP0994103A1 (en) Processes for preparing pesticidal intermediates
EP1000929A1 (en) Process for preparing o-nitrobenzonitriles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21755385

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021755385

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE